Generalized Peeling Skin Syndrome

Watchlist

(log in to enable)

Retrieved

2021-01-23

Source

Orphanet

Trials

—

Genes

CDSN, CHST8, PHF21A, SERPINB8, TGM5, PSORS1C1, IFNG, IL17A, CXCL10, HLA-C, PSS, TNFSF13B, FLG2, TNF, TRAF6, VIP, TLR4, VIPR2, TLR3, TLR2, SSNA1, CNTRL, BTG3, SPINK5, STAT5A, CDC42EP1, SS18L1, RBMS3, IL22, TLR9, DIABLO, FCRL4, FAM167A, TUBA1C, IFNL1, STAT5B, NR0B1, STAT3, SSB, BST2, CD28, CCR8, CST3, CST4, ATN1, EDA, GPI, GTF2I, HLA-A, HLA-B, HLA-DQB1, HLA-DRB1, IFNA1, IFNA13, IL2, IL6, IL10, IL11, IL13, IRAK1, KLRB1, MMP9, MPZ, PMP22, BLK, RO60, CCL25

Drugs

Liarozole, Tazarotene

Interested in hearing about new therapies?

Generalized peeling skin syndrome (PSS) is a form of PSS (see this term) presenting with a generalized distribution. It comprises two sub-types: the non-inflammatory (PSS type A) and the inflammatory (PSS type B) form (see these terms). PSS type A is characterized by generalized white scaling with superficial peeling of the skin, while PSS type B is characterized by superficial patchy peeling of the entire skin with underlying erythroderma, associated with pruritus, and atopy.